Timothy Rolph, Chief Scientific Officer at Akero Therapeutics, Inc. (AKRO), sold 3,800 shares at $31.10 ($118K) on 2024-12-17, disclosed to the SEC on 2024-12-18.
Scheduled sale ($118k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| AKRO | SELL | 2025-09-10 | $1.1M | — | Filing → |
| AKRO | SELL | 2025-08-07 | $1.2M | — | Filing → |
| AKRO | SELL | 2025-07-09 | $1.2M | — | Filing → |